Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetic Retinopathy – Treatment of Diabetic Retinopathy

Treatment of diabetic retinopathy by photocoagulation is of proven efficacy for both proliferative retinopathy and diabetic maculopathy. Transpupillary laser is applied so as to produce a retinal burn. Initially these burns appear as small fluffy areas similar to cotton wool spots…

0010084

0010086

Over time these may evolve into large pigmented scars similar in appearance to moon craters…

0010088

This was common with previous laser treatments; currently the power of the laser burns induces less damage to the retina and the appearance is less dramatic, commonly appearing greenish-grey…

0010090

Panretinal Photocoagulation, PRP

0010092

The rationale for treatment of new vessels (both at the disc and elsewhere) is that ablation of the peripheral retina reduces the overall oxygen requirement of the eye. The ischaemic stimulus is therefore lessened and the new vessels can then regress.

The treatment produces a panretinal covering of non-confluent burns avoiding the macula. Treatment is usually delivered in two sessions, with the inferior half of the retina being treated first (since it is more likely to become inaccessible if a bleed occurs).

Destruction of the peripheral retina can be associated with constriction of the visual fields to such an extent that DVLC criteria for driving are no longer met. Other complications include:

Pain: This varies between individuals and in some cases retrobulbar anaesthesia is required.

Worsening macular oedema: This is usually a temporary phenomenon but maculopathy should ideally be treated before embarking upon PRP.

Focal laser therapy…

0010094

and grid laser therapy…

0010096

will reduce the risk of visual deterioration in patients with diabetic macular oedema by at least 50%. The strategy is to target areas of leakage (e.g. microanuerysms) using focal laser treatment and to use grid treatment for areas of diffuse leakage or capillary non-perfusion.

Note 1: Macular oedema cannot be diagnosed using the indirect ophthalmoscope and fluorescein angiography will be needed to pinpoint areas of capillary fall-out.

0010098

The image above shows areas of capillary fall-out particularly above the macula; these appear dark. The small white dots are retinal microaneurysms and dilated capillaries.

Note 2: Ischaemic maculopathy does not respond to laser treatment.

<< Previous

Diabetic Retinopathy Menu

Introduction
  • Aims and Audience
  • How Images Work
Normal Features
  • General
  • Racial Pigmentation
  • Localised Pigmentation
  • Drusen
  • Myelination
Features of Diabetes
  • Microaneurysms
  • Intraretinal Haemorrhages
  • Hard Exudates
  • Cotton-wool Spots
  • Venous Abnormalities
  • IRMAs
  • Neovascularisation
  • Retinal Detachment
  • Vitreous Haemorrhage
  • Sub-hyaloid Haemorrhage
Classification
  • Background
  • Pre-proliferative
  • Proliferative
Screening
  • Screening
Treatment
  • Treatment

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesAstraZenecaSanofi DiabetesNovo Nordisk

Silver Sponsors

AmgenAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership